BTC Capital Management Inc. Invests $368,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

BTC Capital Management Inc. acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,765 shares of the biopharmaceutical company's stock, valued at approximately $368,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Halozyme Therapeutics by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock worth $634,999,000 after buying an additional 386,618 shares in the last quarter. Snyder Capital Management L P increased its holdings in Halozyme Therapeutics by 2.6% during the 4th quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company's stock worth $199,294,000 after acquiring an additional 105,086 shares during the period. Dimensional Fund Advisors LP lifted its stake in Halozyme Therapeutics by 2.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company's stock worth $92,446,000 after purchasing an additional 47,795 shares in the last quarter. Northern Trust Corp boosted its holdings in Halozyme Therapeutics by 8.7% in the 4th quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company's stock valued at $87,386,000 after purchasing an additional 145,617 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Halozyme Therapeutics by 0.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock valued at $85,254,000 after purchasing an additional 9,780 shares during the period. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Trading Down 4.2%

Shares of NASDAQ HALO traded down $2.33 during midday trading on Tuesday, reaching $53.31. The company had a trading volume of 3,099,309 shares, compared to its average volume of 1,642,776. The stock has a market cap of $6.57 billion, a PE ratio of 15.54, a price-to-earnings-growth ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $70.51. The firm's fifty day moving average price is $58.74 and its 200-day moving average price is $55.73. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $264.86 million during the quarter, compared to the consensus estimate of $231.21 million. During the same quarter in the previous year, the company posted $0.79 earnings per share. The business's revenue was up 35.2% on a year-over-year basis. On average, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 4,497 shares of the company's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the completion of the transaction, the director now owns 28,611 shares of the company's stock, valued at $1,727,246.07. This represents a 13.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 2.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, May 29th. Leerink Partnrs cut Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. Leerink Partners downgraded Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a research report on Tuesday, May 13th. Morgan Stanley cut shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their price objective for the stock from $73.00 to $62.00 in a research report on Wednesday, May 14th. Finally, Wells Fargo & Company boosted their price target on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $61.90.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.